arbutus
reports
third
quarter
financial
results
provides
corporate
update
results
ongoing
phase
clinical
trial
arbutus
subcutaneously
delivered
rnai
agent
subjects
chronic
hepatitis
b
virus
hbv
infection
presented
upcoming
american
association
study
liver
disease
aasld
conference
clinical
collaboration
assembly
biosciences
established
evaluate
arbutus
combination
vebicorvir
assembly
oral
core
capsid
inhibitor
arbutus
oral
capsid
inhibitor
remains
track
completion
cta
studies
end
conference
call
webcast
scheduled
today
et
warminster
globe
newswire
arbutus
biopharma
corporation
nasdaq
abus
biopharmaceutical
company
primarily
focused
developing
cure
people
chronic
hepatitis
b
virus
hbv
infection
well
therapies
treat
coronaviruses
including
today
reports
third
quarter
financial
results
provides
corporate
update
william
collier
president
chief
executive
officer
arbutus
stated
arbutus
focused
discovering
developing
functional
cure
finite
treatment
duration
chronic
hbv
developing
combination
agents
different
mechanisms
action
target
distinct
parts
virus
lifecycle
end
continue
make
steady
progress
ongoing
phase
clinical
trial
lead
clinical
candidate
subcutaneously
delivered
rnai
agent
currently
dosed
chronic
hbv
subjects
four
cohorts
using
mg
dose
every
mg
dose
every
based
upon
clinical
data
generated
thus
far
demonstrated
meaningful
reductions
hbsag
favorable
safety
tolerability
profile
look
forward
presenting
additional
results
ongoing
phase
clinical
trial
part
oral
presentation
upcoming
aasld
conference
pipeline
update
arbutus
currently
conducting
phase
clinical
trial
determine
safety
tolerability
pharmacokinetics
pharmacodynamics
healthy
subjects
subjects
chronic
hbv
infection
arbutus
currently
dosing
two
mg
cohorts
subjects
chronic
hbv
infection
dosing
intervals
every
four
eight
weeks
respectively
results
mg
cohort
dosing
interval
every
four
weeks
additional
data
mg
mg
cohorts
expected
disclosed
part
oral
presentation
upcoming
aasld
conference
november
separately
results
mg
cohort
dosing
interval
every
eight
weeks
mg
cohort
hbv
dna
positive
subjects
expected
fourth
quarter
september
arbutus
reported
additional
data
ongoing
phase
clinical
trial
clinical
data
generated
thus
far
demonstrate
robust
activity
week
mg
mg
achieved
meaningful
reductions
hbsag
remaining
generally
safe
well
tolerated
mean
hbsag
changes
baseline
mg
cohort
b
mg
cohort
c
week
day
mean
iu
ml
standard
error
mean
arbutus
also
currently
dosing
two
mg
cohorts
subjects
dosing
intervals
every
eight
twelve
weeks
respectively
oral
capsid
inhibitor
january
arbutus
selected
oral
capsid
inhibitor
novel
chemical
series
differentiated
competitor
compounds
potential
increased
efficacy
enhanced
resistance
profile
arbutus
continues
expect
completion
cta
studies
end
early
hbv
r
programs
arbutus
drug
discovery
efforts
focused
compounds
current
hbv
pipeline
including
development
oral
shown
compelling
antiviral
effects
multiple
hbv
preclinical
models
arbutus
focused
advancing
lead
optimization
oral
chemical
scaffolds
distinct
arbutus
prior
generation
hbv
rna
destabilizer
candidate
arbutus
also
several
oral
inhibitors
lead
optimization
potentially
capable
reawakening
immune
response
hbv
infected
patients
clinical
collaboration
assembly
biosciences
inc
august
company
entered
clinical
collaboration
agreement
assembly
biosciences
assembly
evaluate
arbutus
clinical
candidate
combination
assembly
lead
hepatitis
b
virus
hbv
core
capsid
inhibitor
candidate
vebicorvir
vbr
nucleos
ide
reverse
transcriptase
inhibitor
nrti
therapy
treatment
patients
chronic
hbv
infection
collaboration
include
randomized
phase
clinical
trial
explore
safety
pharmacokinetics
antiviral
activity
triple
combination
vbr
nrti
compared
double
combinations
vbr
nrti
nrti
trial
expected
initiate
first
half
enroll
approximately
patients
chronic
hbv
infection
gaston
picchio
chief
development
officer
arbutus
stated
clinical
collaboration
companies
share
expertise
costs
potential
provide
proof
concept
data
regarding
safety
efficacy
combining
two
promising
drug
candidates
expedite
efforts
advance
much
needed
hbv
treatment
research
efforts
combat
future
coronavirus
outbreaks
based
extensive
antiviral
drug
discovery
experience
arbutus
established
internal
research
program
identify
new
small
molecule
antiviral
medicines
treat
future
coronavirus
outbreaks
effort
led
michael
sofia
arbutus
chief
scientific
officer
focused
discovery
development
new
molecular
entities
address
specific
viral
targets
including
viral
polymerase
viral
protease
targets
essential
viral
proteins
arbutus
experience
targeting
arbutus
also
joined
forces
covid
r
consortium
support
expedite
efforts
address
pandemic
genevant
sciences
update
july
genevant
sciences
genevant
recapitalized
equity
investment
conversion
previously
issued
convertible
debt
securities
held
roivant
sciences
roivant
arbutus
largest
shareholder
arbutus
participated
recapitalization
genevant
equity
investment
million
following
recapitalization
arbutus
owns
approximately
common
equity
genevant
arbutus
entitlement
receive
future
royalties
sublicensing
revenue
genevant
remains
unchanged
previously
disclosed
april
arbutus
entered
agreement
roivant
launch
genevant
company
focused
discovery
development
commercialization
broad
range
therapeutics
enabled
arbutus
lipid
nanoparticle
lnp
ligand
conjugate
delivery
technologies
arbutus
licensed
exclusive
rights
lnp
ligand
conjugate
delivery
platforms
genevant
applications
outside
hbv
except
extent
certain
rights
already
licensed
third
parties
impact
december
outbreak
novel
strain
coronavirus
identified
wuhan
china
virus
continues
spread
globally
declared
pandemic
world
health
organization
spread
nearly
every
country
world
impact
pandemic
likely
continue
extensive
many
aspects
society
pandemic
resulted
also
likely
continue
result
significant
disruptions
businesses
number
countries
jurisdictions
around
world
implemented
extreme
measures
try
slow
spread
virus
measures
include
closing
businesses
requiring
people
stay
homes
latter
raises
uncertainty
regarding
ability
travel
hospitals
order
participate
clinical
trials
additional
measures
likely
continue
major
impact
clinical
development
least
include
shortages
delays
supply
chain
prohibitions
certain
countries
enrolling
subjects
new
clinical
trials
able
progress
clinical
activities
date
possible
predict
pandemic
negatively
impact
plans
timelines
future
financial
results
cash
cash
equivalents
investments
arbutus
cash
cash
equivalents
investments
totaling
million
september
compared
million
december
nine
months
ended
september
arbutus
used
million
operating
activities
made
million
equity
investment
genevant
cash
outflows
offset
million
net
proceeds
issuance
common
shares
arbutus
atm
program
company
believes
ending
third
quarter
cash
cash
equivalents
investments
million
sufficient
fund
company
operations
net
loss
net
loss
attributable
common
shares
three
months
ended
september
million
basic
diluted
loss
per
common
share
compared
million
basic
diluted
loss
per
common
share
three
months
ended
september
net
loss
attributable
common
shares
three
months
ended
september
included
impairment
charges
million
research
development
ipr
intangible
asset
million
goodwill
reduce
carrying
values
zero
well
corresponding
income
tax
benefit
million
related
decrease
deferred
tax
liability
associated
ipr
intangible
assets
ii
million
expense
related
arbitration
award
company
arbitration
university
british
columbia
net
loss
attributable
common
shares
three
months
ended
september
included
expense
accrual
coupon
company
convertible
preferred
shares
million
million
respectively
expense
proportionate
share
genevant
net
losses
million
third
quarter
million
third
quarter
operating
expenses
research
development
expenses
million
three
months
ended
september
compared
million
decrease
research
development
expenses
three
months
ended
september
versus
period
due
primarily
lower
clinical
expenses
general
administrative
expenses
million
three
months
ended
september
compared
million
period
increase
due
primarily
increased
expenses
increase
insurance
premiums
outstanding
shares
company
approximately
million
common
shares
issued
outstanding
september
addition
company
approximately
million
stock
options
outstanding
million
convertible
preferred
shares
outstanding
including
annual
interest
form
additional
preferred
shares
mandatorily
convertible
approximately
million
common
shares
october
unaudited
condensed
consolidated
statements
loss
thousands
except
share
per
share
data
three
months
ended
september
nine
months
ended
september
revenue
collaborations
licenses
royalty
revenue
total
revenue
operating
expenses
research
development
general
administrative
depreciation
amortization
change
fair
value
contingent
consideration
site
consolidation
impairment
intangible
assets
impairment
goodwill
arbitration
loss
operations
income
loss
interest
income
interest
expense
foreign
exchange
gain
loss
equity
investment
loss
total
loss
loss
income
taxes
income
tax
benefit
net
loss
dividend
accretion
convertible
preferred
shares
net
loss
attributable
common
shares
loss
per
share
basic
diluted
weighted
average
number
common
shares
basic
diluted
unaudited
condensed
consolidated
balance
sheets
thousands
september
december
cash
cash
equivalents
investments
marketable
securities
current
accounts
receivable
current
assets
total
current
assets
property
equipment
net
accumulated
depreciation
right
use
asset
assets
total
assets
accounts
payable
accrued
liabilities
options
lease
liability
current
total
current
liabilities
liability
related
sale
future
royalties
contingent
consideration
lease
liability
total
stockholders
equity
total
liabilities
stockholders
equity
unaudited
condensed
consolidated
statements
cash
flow
thousands
nine
months
ended
september
net
loss
impairment
intangible
assets
goodwill
deferred
income
tax
benefit
items
changes
working
capital
net
cash
used
operating
activities
net
cash
provided
investing
activities
net
cash
provided
financing
activities
effect
foreign
exchange
rate
changes
cash
cash
equivalents
increase
cash
cash
equivalents
cash
cash
equivalents
beginning
period
cash
cash
equivalents
end
period
investments
marketable
securities
cash
cash
equivalents
investments
end
period
conference
call
webcast
today
arbutus
hold
conference
call
webcast
today
thursday
november
eastern
time
provide
corporate
update
access
live
webcast
call
investors
section
arbutus
website
directly
live
webcast
alternatively
dial
reference
conference
id
archived
webcast
available
arbutus
website
event
alternatively
may
access
replay
conference
call
calling
reference
conference
id
rna
interference
rnai
therapeutic
targeted
hepatocytes
using
arbutus
novel
covalently
conjugated
galnac
delivery
technology
enables
subcutaneous
delivery
inhibits
viral
replication
reduces
hbv
antigens
including
hepatitis
b
surface
antigen
preclinical
models
reducing
hepatitis
b
surface
antigen
thought
key
prerequisite
enable
reawakening
patient
immune
system
respond
virus
based
upon
clinical
data
generated
thus
far
ongoing
phase
clinical
trial
demonstrated
positive
safety
tolerability
data
meaningful
reductions
hepatitis
b
surface
antigen
oral
hbv
capsid
inhibitor
hbv
core
protein
assembles
capsid
structure
required
viral
replication
current
therapy
hbv
primarily
nucleos
ide
analogues
work
inhibiting
viral
polymerase
significantly
reduce
virus
replication
completely
capsid
inhibitors
inhibit
replication
preventing
assembly
functional
viral
capsids
also
shown
inhibit
uncoating
step
viral
life
cycle
thus
reducing
formation
new
covalently
closed
circular
dna
cccdna
genetic
reservoir
virus
uses
replicate
hbv
chronic
hepatitis
b
virus
hbv
infection
debilitating
disease
liver
afflicts
million
people
worldwide
million
people
china
estimated
world
health
organization
hbv
global
epidemic
affects
people
hepatitis
c
virus
hcv
hiv
infection
higher
morbidity
mortality
rate
hbv
leading
cause
chronic
liver
disease
need
liver
transplantation
one
million
people
worldwide
die
every
year
causes
current
standard
care
patients
chronic
hbv
infection
suppressive
treatment
medications
reduce
eliminate
virus
resulting
low
cure
rates
significant
unmet
need
new
therapies
treat
hbv
arbutus
arbutus
biopharma
corporation
publicly
traded
nasdaq
abus
biopharmaceutical
company
primarily
dedicated
discovering
developing
commercializing
cure
people
chronic
hepatitis
b
virus
hbv
infection
company
advancing
multiple
drug
product
candidates
may
combined
potentially
curative
regimen
chronic
hbv
infection
arbutus
also
initiated
drug
discovery
development
effort
treating
coronaviruses
including
information
visit
statements
information
press
release
contains
statements
within
meaning
section
securities
act
section
securities
exchange
act
information
within
meaning
canadian
securities
laws
collectively
statements
statements
press
release
include
statements
arbutus
expectations
regarding
timing
clinical
development
product
candidates
including
arbutus
expectations
results
mg
cohorts
mg
cohorts
hbv
dna
positive
subjects
disclosed
part
oral
presentation
upcoming
assld
conference
november
results
mg
cohort
dosing
interval
every
eight
weeks
mg
cohort
hbv
dna
positive
subjects
expected
fourth
quarter
cta
studies
complete
end
arbutus
expectation
initiate
phase
clinical
trial
vbr
nrti
first
half
enroll
approximately
patients
chronic
hbv
infection
arbutus
planned
cash
burn
guidance
potential
safety
efficacy
arbutus
product
candidates
arbutus
expectations
regarding
internal
external
research
efforts
combat
future
coronavirus
outbreaks
expected
sufficiency
arbutus
ending
third
quarter
cash
cash
equivalents
investments
sufficient
fund
operations
arbutus
expectations
regarding
technology
licensed
genevant
arbutus
expectations
regarding
effect
pandemic
business
respect
statements
contained
press
release
arbutus
made
numerous
assumptions
regarding
among
things
timely
receipt
expected
payments
effectiveness
timeliness
preclinical
studies
clinical
trials
usefulness
data
timeliness
regulatory
approvals
continued
demand
arbutus
assets
stability
economic
market
conditions
arbutus
considers
assumptions
reasonable
assumptions
inherently
subject
significant
business
economic
competitive
market
social
uncertainties
contingencies
including
uncertainties
contingencies
related
ongoing
pandemic
additionally
known
unknown
risk
factors
could
cause
arbutus
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
contained
herein
known
risk
factors
include
among
others
anticipated
studies
clinical
trials
may
costly
take
longer
complete
anticipated
may
never
initiated
completed
may
generate
results
warrant
future
development
tested
drug
candidate
changes
arbutus
strategy
regarding
product
candidates
clinical
development
activities
arbutus
may
receive
necessary
regulatory
approvals
clinical
development
arbutus
products
economic
market
conditions
may
worsen
market
shifts
may
require
change
strategic
focus
ongoing
pandemic
could
significantly
disrupt
clinical
development
programs
complete
discussion
risks
uncertainties
facing
arbutus
appears
arbutus
annual
report
form
arbutus
quarterly
reports
form
arbutus
continuous
periodic
disclosure
filings
available
statements
herein
qualified
entirety
cautionary
statement
arbutus
disclaims
obligation
revise
update
statements
publicly
announce
result
revisions
statements
contained
herein
reflect
future
results
events
developments
except
required
law
contact
information
investors
media
william
collier
president
ceo
phone
email
ir
